Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

23.8%

5 terminated/withdrawn out of 21 trials

Success Rate

68.8%

-17.8% vs industry average

Late-Stage Pipeline

19%

4 trials in Phase 3/4

Results Transparency

100%

11 of 11 completed trials have results

Key Signals

1 recruiting11 with results

Enrollment Performance

Analytics

Phase 2

8(42.1%)

Phase 1

7(36.8%)

Phase 3

3(15.8%)

Phase 4

1(5.3%)

19Total

Phase 2(8)

Phase 1(7)

Phase 3(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT06027268Phase 2Active Not Recruiting

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

Role: collaborator

NCT05578326Phase 2Recruiting

Study of Trilaciclib and Lurbinectidin

Role: collaborator

NCT03041311Phase 2Completed

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Role: lead

NCT02514447Phase 1Completed

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Role: lead

NCT04887831Phase 2Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

Role: lead

NCT05113966Phase 2Terminated

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Role: lead

NCT04607668Phase 3Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Role: lead

NCT04799249Phase 3Completed

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Role: lead

NCT04902885Phase 3Completed

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

Role: collaborator

NCT05112536Phase 2Completed

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Role: lead

NCT05071703Phase 4Completed

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

Role: collaborator

NCT03455829Phase 1Completed

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Role: lead

NCT05826756Unknown

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

Role: collaborator

NCT04863248Phase 2Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Role: lead

NCT02983071Phase 1Unknown

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT03455270Phase 1Completed

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Role: lead

NCT02978716Phase 2Terminated

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Role: lead

NCT04504513Unknown

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Role: lead

NCT02499770Phase 1Completed

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Role: lead

NCT02243150Phase 1Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

Role: lead